Cingulate Past Earnings Performance
Past criteria checks 0/6
Cingulate's earnings have been declining at an average annual rate of -18.6%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually.
Key information
-18.6%
Earnings growth rate
51.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -619.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Cingulate makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -19 | 6 | 0 |
| 31 Mar 24 | 0 | -23 | 7 | 0 |
| 31 Dec 23 | 0 | -24 | 7 | 0 |
| 30 Sep 23 | 0 | -21 | 8 | 0 |
| 30 Jun 23 | 0 | -19 | 8 | 0 |
| 31 Mar 23 | 0 | -17 | 8 | 0 |
| 31 Dec 22 | 0 | -18 | 9 | 0 |
| 30 Sep 22 | 0 | -16 | 7 | 0 |
| 30 Jun 22 | 0 | -27 | 7 | 0 |
| 31 Mar 22 | 0 | -24 | 6 | 0 |
| 31 Dec 21 | 0 | -21 | 4 | 0 |
| 30 Sep 21 | 0 | -19 | 3 | 0 |
| 30 Jun 21 | 0 | -5 | 2 | 0 |
| 31 Mar 21 | 0 | -6 | 2 | 0 |
| 31 Dec 20 | 0 | -7 | 2 | 0 |
Quality Earnings: CING is currently unprofitable.
Growing Profit Margin: CING is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CING is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare CING's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CING is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: CING has a negative Return on Equity (-619.24%), as it is currently unprofitable.